Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Genzyme Expands Fabrazyme Manufacturing Capacity | Contract Pharma

What are you searching for?

Sign in
Breaking News

Genzyme Expands Fabrazyme Manufacturing Capacity

Invests $80 million in Framingham site

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genzyme, a Sanofi company, is investing $80 million to build a new downstream processing facility for Fabrazyme (agalsidase beta), significantly expanding purification capacity to support anticipated growth in demand. The new plant will be adjacent to the new Fabrazyme cell culture manufacturing site in Framingham, MA.
 
Downstream processing involves the purification of material harvested from the cell culture manufacturing process. The final product is an intravenous (IV) infusion, which is formulated and fill-finished in a separate facility in Waterford, Ireland and shipped to multiple distribution centers for labeling, packaging and shipping.
 
“As we continue to meet the global demands for Fabrazyme and build inventory, our focus also remains on the future needs of the global Fabry community,” said Genzyme president and chief executive officer, David Meeker, M.D. “Following last year’s regulatory approvals of our manufacturing facility in Framingham and a new vial filling line at our plant in Waterford, Ireland, we continue to execute on our global manufacturing strategy, enhancing our capabilities across the entire manufacturing process for Fabrazyme.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics